MBX Biosciences to Announce Topline Results from Phase 2 Trial of Canvuparatide for Chronic Hypoparathyroidism on September 22

MBX Biosciences will announce Phase 2 trial results for canvuparatide in chronic hypoparathyroidism on September 22.

Quiver AI Summary

MBX Biosciences, Inc. announced that it will release topline results from its Phase 2 clinical trial of canvuparatide, a potential once-weekly treatment for chronic hypoparathyroidism, during an investor webcast on September 22. The conference call is set for 8 am ET, and interested individuals can join via webcast or phone. MBX focuses on developing precision peptide therapies for endocrine and metabolic disorders using its proprietary PEP™ platform and aims to address significant unmet medical needs within this market. Additional information can be found on the company's website.

Potential Positives

MBX Biosciences is set to provide topline results from its Phase 2 clinical trial of canvuparatide, which generates anticipation for potential positive outcomes that could strengthen its market position.
The company is actively engaging with investors by hosting a conference call and webcast to discuss trial results, indicating transparency and a commitment to investor relations.
The focus on a novel precision peptide therapy for chronic hypoparathyroidism addresses a significant unmet medical need, positioning the company in a promising therapeutic area with large market opportunities.

Potential Negatives

The announcement of topline results from the clinical trial may indicate that previous expectations for results were not met, as companies often only disclose results when they are favorable.
The timing of the webcast suggests a need for immediate communication with investors, which could imply a potential urgency regarding the trial results that may not be entirely positive.
The focus on chronic hypoparathyroidism, a niche area, may indicate a limited market opportunity compared to more common conditions, raising concerns about the scalability and investment appeal of the company's pipeline.

FAQ

What is MBX Biosciences focused on?

MBX Biosciences focuses on developing novel precision peptide therapies for endocrine and metabolic disorders.

When will MBX Biosciences announce the Phase 2 trial results?

The topline results from the Phase 2 clinical trial will be announced on September 22, 2025.

How can I access the investor webcast?

You can access the investor webcast on the company's website or by dialing 1-877-407-0779 (US).

What is canvuparatide being tested for?

Canvuparatide is being tested as a potential treatment for patients with chronic hypoparathyroidism.

Where can I find more information about MBX Biosciences?

You can learn more about MBX Biosciences by visiting their website at https://mbxbio.com/.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$MBX Insider Trading Activity

$MBX insiders have traded $MBX stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $MBX stock by insiders over the last 6 months:

ORA H. PESCOVITZ purchased 7,693 shares for an estimated $45,311

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$MBX Analyst Ratings

Wall Street analysts have issued reports on $MBX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Jefferies issued a "Buy" rating on 08/15/2025
Mizuho issued a "Outperform" rating on 08/05/2025
Oppenheimer issued a "Outperform" rating on 07/16/2025
JMP Securities issued a "Market Outperform" rating on 04/10/2025
Guggenheim issued a "Buy" rating on 04/10/2025

To track analyst ratings and price targets for $MBX, check out Quiver Quantitative's $MBX forecast page.

$MBX Price Targets

Multiple analysts have issued price targets for $MBX recently. We have seen 5 analysts offer price targets for $MBX in the last 6 months, with a median target of $38.0.

Here are some recent targets:

Roger Song from Jefferies set a target price of $36.0 on 08/15/2025
Uy Ear from Mizuho set a target price of $38.0 on 08/05/2025
Trevor Allred from Oppenheimer set a target price of $38.0 on 07/16/2025
Jonathan Wolleben from JMP Securities set a target price of $38.0 on 04/10/2025
Seamus Fernandez from Guggenheim set a target price of $44.0 on 04/10/2025

Full Release

CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22.

The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast here or dial 1-877-407-0779 (US) or 1-201-389-0914 (international). The live and archived webcast of the call and slide presentation will be available in the Investors section of the Company’s website at https://investors.mbxbio.com/news-events/events.

About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn .

Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
[email protected]
(937) 232-4889

Investor Contact:
Jim DeNike
MBX Biosciences
[email protected]